Piper Sandler Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)

Research analysts at Piper Sandler started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report issued on Wednesday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $12.00 price target on the stock. Piper Sandler’s target price would indicate a potential upside of 278.55% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on CMPX. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group increased their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $11.29.

Compass Therapeutics Stock Down 6.2 %

Compass Therapeutics stock opened at $3.17 on Wednesday. Compass Therapeutics has a twelve month low of $0.76 and a twelve month high of $4.08. The company’s 50-day moving average price is $2.34 and its 200-day moving average price is $1.84. The company has a market cap of $436.16 million, a PE ratio of -8.57 and a beta of 1.17.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $11,293,000. Tang Capital Management LLC grew its position in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after buying an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC grew its position in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after buying an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC grew its position in Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock worth $395,000 after purchasing an additional 227,864 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.